Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Defactinib + RO5126766 |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Defactinib | VS-6063|PF-04554878 | FAK inhibitor 15 | Defactinib (VS-6063) inhibits FAK, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and survival (PMID: 31739184). | |
| RO5126766 | Avutometinib|VS-6766|VS6766|VS 6766|CH5126766|CH-5126766|R-7304|RG-7304 | MEK inhibitor (Pan) 26 MEK1 Inhibitor 26 MEK2 Inhibitor 24 RAF Inhibitor (Pan) 28 | RO5126766 (VS-6766) is a RAF/MEK inhibitor, which potentially leads to decreased tumor cell growth and inhibition of tumor growth (PMID: 34288272). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06487221 | Phase II | Defactinib + RO5126766 | Avutometinib and Defactinib in Diffuse Gastric Cancer | Recruiting | USA | 0 |
| NCT04720417 | Phase II | Defactinib + RO5126766 | Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma | Active, not recruiting | USA | 0 |
| NCT03875820 | Phase I | Defactinib + RO5126766 | Phase I Trial of Defactinib and VS-6766. (FRAME) | Active, not recruiting | GBR | 0 |
| NCT06194929 | Phase Ib/II | Defactinib + Encorafenib + RO5126766 Defactinib + RO5126766 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE) | Recruiting | USA | 0 |
| NCT05787561 | Phase II | Defactinib + RO5126766 | A Study of VS-6766 and Defactinib in People With Mesonephric Gynecologic Cancer | Recruiting | USA | 0 |
| NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
| NCT06072781 | Phase III | Paclitaxel Pegylated liposomal doxorubicin Defactinib + RO5126766 Topotecan Anastrozole Letrozole | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | AUS | 0 |
| NCT05512208 | Phase II | Defactinib + RO5126766 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) | Recruiting | USA | 0 |
| NCT06630260 | Phase Ib/II | Defactinib + RO5126766 + Temozolomide Defactinib + RO5126766 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (5G-RUBY) | Recruiting | GBR | 0 |
| NCT04620330 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202) | Completed | USA | ITA | FRA | ESP | DEU | 0 |
| NCT04625270 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
CKB BOOST